Interestingly, genetic and pharmacological inactivation of NOX1 activity prevents the angiogenic switch and the growth of experimental tumors derived from NSCLC LKB1-deficient cancer cells [42]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.